• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Longboard Pharmaceuticals Inc (NQ: LBPH )

    35.82 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 12
    Open 35.82
    Bid (Size) 35.87 (1)
    Ask (Size) 36.63 (2)
    Prev. Close 35.82
    Today's Range 35.82 - 35.82
    52wk Range 3.600 - 40.48
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    3 Russell 2000 Growth Stocks That Could Be Worth the Risk
    These three small-cap stocks could deliver hefty returns if the central bank cuts rates. 
    Via The Motley Fool
    Topics Economy
    Exposures Interest Rates
    Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Longboard Pharmaceuticals, Inc.
    Via Business Wire

    Performance

    YTD
    +42.71%
    +42.71%
    1 Month
    +76.11%
    +76.11%
    3 Month
    +86.08%
    +86.08%
    6 Month
    +37.77%
    +37.77%
    1 Year
    +422.92%
    +422.92%

    More News

    Read More
    Top 3 Health Care Stocks That May Crash This Quarter
    Via Benzinga
    Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)
    From Longboard Pharmaceuticals, Inc.
    Via Business Wire
    Recap: Longboard Pharmaceuticals Q4 Earnings
    Via Benzinga
    Looking Into Longboard Pharmaceuticals's Recent Short Interest
    Via Benzinga
    Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
    From Longboard Pharmaceuticals, Inc.
    Via Business Wire
    Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Longboard Pharmaceuticals, Inc.
    Via Business Wire
    Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Longboard Pharmaceuticals, Inc.
    Via Business Wire
    LBPH Stock Earnings: Longboard Pharmaceuticals Beats EPS for Q1 2024
    Via InvestorPlace
    Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
    From Longboard Pharmaceuticals, Inc.
    Via Business Wire
    Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
    From Longboard Pharmaceuticals, Inc.
    Via Business Wire
    Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Longboard Pharmaceuticals, Inc.
    Via Business Wire
    Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
    From Longboard Pharmaceuticals, Inc.
    Via Business Wire
    Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Longboard Pharmaceuticals, Inc.
    Via Business Wire
    Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Longboard Pharmaceuticals, Inc.
    Via Business Wire
    Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February
    From Longboard Pharmaceuticals, Inc.
    Via Business Wire
    Forget the "Magnificent Seven" -- This Stock Has Nearly Quadrupled in 2024, and Wall Street Thinks It Can Go a Lot Higher
    Via The Motley Fool
    Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Cantor Fitzgerald Maintains Overweight Rating for Longboard Pharmaceuticals: Here's What You Need To Know
    Via Benzinga
    Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From Longboard Pharmaceuticals, Inc.
    Via Business Wire
    This biotech stock has surged over 300% this week
    Via MarketBeat
    Jim Cramer: This Energy Firm Has 'Good Growth, Good Yield' But As For IonQ? Ixnay
    Via Benzinga
    Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
    From Longboard Pharmaceuticals, Inc.
    Via Business Wire
    Why Longboard Pharmaceuticals Stock Is Falling
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.